Loading
BioRestorative Therapies, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 10 Apr 2024.
BioRestorative Therapies, Inc.: what insiders have been doing
BioRestorative Therapies, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Over the twelve months to 18 October 2026, 2 filings were filed, from 2 insiders.
The filings describe grants, exercises and other transfers rather than trades on the open market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Insider buying of BioRestorative Therapies, Inc. has been absent for the past year.
Compared with its exchange (5,814 companies, median 19 filings), a count of 2 filings is below the norm. Looking back to 2021, when coverage begins, insiders filed 65 purchases and 4 sales. The 10-K for the year ended 31 December 2025 shows -14.2 m USD of net income.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
81
Thresholds
n/a
Buy Volume
€623,619
65 ops. · all time
Sell Volume
€15,987
4 ops. · all time
Since the insiders bought
- +36.1%Entry US$1.32 · Close at T+365 US$1.79
- +70.7%Entry US$1.40 · Close at T+365 US$2.39
- -19.0%Entry US$1.89 · Close at T+365 US$1.53
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.20
Analyst consensus
2 analystsUS$1.00Target US$8.00(+3822%)US$15.00
Income statement
RevenueUS$359.7k
Gross profitUS$335.9k93% margin
EBITDA-US$15.4M-4292% margin
Net income-US$14.2M-3959.4% margin
Valuation
PER (forward)-0.4x
P/Book1.7x
Beta0.74
Balance sheet & cash
Market capUS$5.2M
Free Cash Flow-US$10.9M
Debt / Equity1%
Profitability & ownership
ROE-241.1%
ROA-118.8%
% insiders10.4%
% institutions7.7%
Last declaration on 20 October 2025
Declarations81 total
11,719 shares@ US$1.6011.3% of flowComon StockSEC:0001021771-25-000141:0
15,625 shares@ US$1.6013.8% of flowCommon StockSEC:0001021771-25-000140:0
1,112 shares@ US$1.580.4% of flowCommon StockSEC:0001021771-24-000184:0
476 shares@ US$1.130.3% of flowCommon StockSEC:0001021771-24-000091:0
Canonical exit: 7 Jul 2024 (T+90)
17,193 shares@ US$1.3915.5% of flowCommon StockSEC:0001021771-24-000079:0
17,633 shares@ US$1.3914.6% of flowCommon StockSEC:0001021771-24-000077:0
73,959 shares@ US$1.2520.1% of flowCommon StockSEC:0001021771-24-000038:0
Canonical exit: 8 May 2024 (T+90)
36,374 shares@ US$1.3811.0% of flowCommon StockSEC:0001021771-24-000035:0
Canonical exit: 7 May 2024 (T+90)
250 shares@ US$1.8770.1% of flowCommon StockSEC:0001021771-23-000118:0
278 shares@ US$1.890.1% of flowCommon StockSEC:0001021771-23-000116:0
10,000 shares@ US$1.543.4% of flowCommon StockSEC:0001021771-23-000098:0
Canonical exit: 13 Dec 2023 (T+90)
2,200 shares@ US$1.702.3% of flowCommon StockSEC:0001021771-23-000096:0
Canonical exit: 14 Dec 2023 (T+90)
500 shares@ US$2.890.3% of flowCommon StockSEC:0001021771-23-000092:0
Canonical exit: 26 Oct 2023 (T+90)
800 shares@ US$1.53250.7% of flowCommon StockSEC:0001021771-23-000090:0
Canonical exit: 12 Dec 2023 (T+90)
2,887 shares@ US$1.963.4% of flowCommon StockSEC:0001021771-23-000088:0
Canonical exit: 5 Dec 2023 (T+90)
4,954 shares@ US$2.227.2% of flowCommon StockSEC:0001021771-23-000086:0
Canonical exit: 29 Nov 2023 (T+90)
1,000 shares@ US$2.800.6% of flowCommon StockSEC:0001140361-23-036665:0
Canonical exit: 25 Oct 2023 (T+90)
4,200 shares@ US$2.446.0% of flowCommon StockSEC:0001140361-23-036103:0
Canonical exit: 23 Oct 2023 (T+90)
747 shares@ US$3.561.7% of flowCommon StockSEC:0001021771-23-000034:0
Canonical exit: 29 Jun 2023 (T+90)
6,729 shares@ US$2.9213.0% of flowCommon StockSEC:0001021771-23-000028:0
6,729 shares@ US$2.9211.9% of flowCommon StockSEC:0001021771-23-000026:0
100 shares@ US$2.780.1% of flowCommon StockSEC:0001567619-23-004348:0
Canonical exit: 28 Feb 2023 (T+90)
374 shares@ US$2.990.7% of flowCommon StockSEC:0001567619-23-003891:0
374 shares@ US$2.990.7% of flowCommon StockSEC:0001567619-23-003875:0
400 shares@ US$3.10340.7% of flowCommon StockSEC:0001567619-23-001697:0
Canonical exit: 2 May 2023 (T+90)
25 of 81 declarations
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (ticker: BRTX) is a United States-based regenerative medicine company listed on NASDAQ. Headquartered in Melville, New York, the company develops stem cell-based therapies and related products, with an emphasis on adult stem cell science and translational medicine. From an equity-analyst perspective, BRTX should be viewed as a clinical-stage micro-cap biotech with meaningful binary risk, but also with upside optionality if its lead assets continue to advance through clinical and regulatory milestones.
The company was founded by scientists and researchers focused on addressing unmet medical needs in highly prevalent conditions. Over time, it consolidated its operations in Melville, Long Island, where it maintains its headquarters and laboratory capabilities. BioRestorative’s business model is centered on two core programs. Its Disc/Spine program, branded brtxDISC, is led by BRTX-100, an autologous mesenchymal stem cell therapy derived from the patient’s own bone marrow and designed for chronic disc-related pain conditions. Its second platform, ThermoStem, targets metabolic disorders such as obesity through cell-based approaches involving brown adipose tissue biology and associated exosomes.
Read moreShow less
In competitive terms, BioRestorative operates in a highly specialized and crowded regenerative medicine field where success depends on clinical differentiation, intellectual property strength, manufacturing know-how, and the ability to navigate FDA pathways. The addressable markets are large, particularly for chronic spinal pain and metabolic disease, but the company remains pre-commercial and therefore does not yet have the scale, revenue base, or de-risked profile of larger biotech peers. Investors are therefore largely underwriting scientific execution rather than current operating performance.
Recent developments have been important. In 2025 and 2026, BioRestorative highlighted expanded Phase 2 data for BRTX-100, completion of enrollment in a randomized, double-blind, sham-controlled Phase 2 trial across 15 U.S. sites, and continued interaction with the FDA. The company also completed a $5 million public offering and has been managing capital carefully, which is typical for development-stage biotech. In April 2026, it announced a strategic collaboration with 203 Creates to build and commercialize a biocosmeceutical platform, showing an effort to broaden its commercial narrative beyond core clinical programs. For investors, BRTX combines early-stage regenerative medicine exposure with long-duration value creation potential, but also substantial clinical, financing, and execution risk.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
